Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Epilepsy - Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

30 Jan, 2019, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

LAS VEGAS, January 30, 2019 /PRNewswire/ --

United States account for highest prevalent cases of Epilepsy with 3,588,984 prevalent cases in 2017 followed by Germany among 7MM

  1. According to DelveInsight, the prevalent cases of Epilepsy was 6,980,430 in 2017 in 7 MM and, is expected to increase during the study period i.e., 2017-2028.
  2. There are approximately 30-40 treatment medications in market for Epilepsy, out of which more than 50% have gone off patent.
  3. The Epilepsy Therapeutics market has seen a total sales of 2.9 billion in 7MM in 2017.

(Albany, US) DelveInsight has introduced Epilepsy - Market Insights, Epidemiology and Market Forecast-2028 report into its portfolio as its latest offering.

     (Logo: https://mma.prnewswire.com/media/776895/DelveInsight_Logo.jpg )

Click here to get a free sample report: https://www.delveinsight.com/dev-sample.php?form_name=Epilepsy---Market-Insights,-Epidemiology-and-Market-Forecast-2028

Key topics covered 

  1. The report provides the in-depth analysis of the disease overview and diagnostic trends.
  2. It covers historical and current patient pool and forecasted trends for 7
  3. The report encloses the detailed analysis of marketed drugs, Phase III and late Phase II pipeline drugs. The key cross competition which evaluates the drugs on several parameters will provide additional insights.
  4. It will provide detailed insights about the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market.
  5. The insights related to unmet needs, drivers-barriers and demand of better technology are also provided in this report

"Epilepsy market is expected to grow during the forecasted period of 2019-2028 owing to the launch of approximately 9 drugs (presently in Phase III)."

The current market for Epilepsy is dominated by use of several Antiepileptic Drugs (AEDs) which can be broadly classified as per their mechanism of action. These are GABA Enhancers/ Inhibitors, Ca Channel Blockers, Na Channel Blockers, medication inhibiting both Ca and Na Channel Blockers, AMPA Receptor Blockade, the new AEDs falling under the category of Synaptic vesicle protein 2a (SV2a) vesicle inhibition, the plant based approved cannabidiol, Epidiolex, which is the only approved therapy in this category.

There are a plethora of marketed drugs in the market. Some of them have been listed below:

  1. Trokendi XR
  2. Oxtellar XR
  3. Sabril
  4. Epidiolex
  5. Fycompa

And many others

Some of the companies that are covered in the report are:

  1. Supernus Pharmaceuticals
  2. Lundbeck
  3. Greenwich Biosciences
  4. Eisai
  5. Pfizer

And many others

Get a WebEx demo : https://www.delveinsight.com/dev-sample.php?form_name=Epilepsy---Market-Insights,-Epidemiology-and-Market-Forecast-2028

Table of contents 

1. Key Insights

2. Epilepsy Market Overview at a Glance

3. Disease Background and Overview: Epilepsy

4. Epidemiology and Patient Population

5. Country Wise-Epidemiology of Epilepsy

5.1. United States

5.2. EU5 Countries

5.3. Germany

5.4. France

5.5. Italy

5.6. Spain

5.7. United Kingdom

5.8. Japan

6. Treatment

7. Treatment Algorithm on Epilepsy

8. United States Guideline on Epilepsy

9. European Guideline on Epilepsy

10. Unmet Needs

11. Marketed Drugs

11.1. Trokendi XR: Supernus Pharmaceuticals

11.2. Oxtellar XR: Supernus Pharmaceuticals

11.3. Sabril: Lundbeck

11.4. Epidiolex: Greenwich Biosciences

11.5. Fycompa: Eisai

11.6. Vimpat: UCB

11.7. Lyrica: Pfizer

11.8. Banzel: Eisai

11.9. Briviact: UCB Pharma

11.10. Keppra: UCB

11.11. Keppra XR (levetiracetam XR): UCB

11.12. Topamax: Janssen

11.13. Lamictal: GlaxoSmithKline

11.14. Neurontin: Pfizer

11.15. Zonegran: Eisai

11.16. Trileptal: Novartis

11.17. Zebinix (Aptiom): Dainippon Sumitomo Pharma/Eisai

12. Emerging Drugs

13. Key Cross Competition (Late-Stage Emerging Drugs)

14. Key Cross Competition (Mid-Stage Emerging Drugs)

14.1. Cenobamate: SK Biopharmaceuticals

14.2. USL261: UCB

14.3. NRL-1: Neurelis

14.4. Ganaxolone: Marinus Pharmaceuticals

14.5. SAGE-547: Sage Therapeutics

14.6. Fintepla: Zogenix

14.7. AQST-203: Aquestive Therapeutics

14.8. Cannabidiol: INSYS Therapeutics

14.9. Padsevonil: UCB

14.10. Staccato alprazolam: Engage Therapeutics

14.11. ZYN002: Zynerba Pharma

14.12. GWP42006: GW Pharmaceuticals

14.13. CX-8998: Cavion

15. Epilepsy: 7 Major Market Analysis

16. The United States Market Outlook

17. EU-5 Countries: Market Outlook

18. Japan: Market Outlook

19. Market Drivers

20. Market Barriers

21. Appendix

22. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330

Modal title

Also from this source

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

DelveInsight's NADPH Oxidase (NOX)-Replacement Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a...

Frontotemporal Dementia Market Sees Rise in Precision Medicine and Gene Therapy Approaches | DelveInsight

Frontotemporal Dementia Market Sees Rise in Precision Medicine and Gene Therapy Approaches | DelveInsight

DelveInsight's Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment practices, frontotemporal...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Mental Health

Mental Health

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.